Bosselaar, Sabine
Dhelin, Lucile
Dautel, Ellena
Titecat, Marie
Duthoy, Stéphanie
Stelmaszczyk, Marie
Delory, Nathan
De Sousa Violante, Madeleine
Machuron, François
Ait-Abderrahim, Hassina
Desreumaux, Pierre
Foligné, Benoit
Monnet, Céline
Article History
Received: 14 February 2024
Accepted: 12 June 2024
First Online: 29 June 2024
Declarations
:
: Fecal samples were collected during medical care at Lille University Hospital by Pr. Desreumaux during routine gastroenterological consultations and Bacterial strains were further isolated from these samples by IBD Biotech, as secondary use of biological material, as approved by the French law (Article L1211-2). A local ethics committee (Comité de Protection des Personnes Nord Ouest IV, CHRU Lille, France) approved the study (No. DC-2008–642) and all subjects signed clear informed consent.
: Not applicable.
: This study was a collaboration between Lesaffre International and Infinite (Inserm, CHU Lille, U1286, France). SB, LD, ED, SD, MS, ND, MDSV, FM, HAA and CM are employees of Lesaffre International, who funded this study. P.D. reports personal fees from Lesaffre and several pharmaceutical companies, Abbott, Amgen, Biocodex, Biofortis, Biogen, Biokuris, Ferring, Fresenius, Janssen Kitozyme, MSD, Norgine, Pfizer, Sandoz, Shire, Takeda, Tillotts, and UCB, outside of the submitted work. Other authors declared no competing interests.